| Exclusion Criteria: | 1) Receiving concurrent administration of any other systemic or localized anticancer therapy (including radiation, PUVA, and photopheresis)
2) Unable to swallow tablets
3) Receiving high potency oral or topical steroids. Low potency oral steroid equivalent to or less than 10 mg prednisone (or equivalent) per day or low- to mid-potency topical steroids may be permitted in patients who have been on a stable dose for at least 4 weeks prior to screening. Oral or topical antihistamine is allowed.
4) Unable to discontinue use of carbamazepine, phenobarbital, or phenytoin
5) Prior treatment with enzastaurin
6) Have a serious concomitant systemic disorder that could preclude the patient from benefiting or completing the study based on the discretion of the investigator
7) Patients must be disease free of prior malignancies for >/= 2 years with exception of currently treated squamous cell and basal cell carcinoma of the skin, melanoma in situ with histologically confirmed free margins, or carcinoma in situ of the cervix.
8) Have a serious cardiac condition such as myocardial infarction within past 6 months, angina, or heart disease as defined by the New York Heart Association (NYHA) Class III or IV
9) Have ECG abnormalities, including baseline 12-lead ECG with QTc interval of > 430 msec in males or > 450 msec in females, or QRS duration of > 100 msec
10) Known to be HIV positive.
11) Are pregnant or breastfeeding
12) Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry |